Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Anaptysbio Inc (NQ: ANAB ) 21.00 +2.13 (+11.29%) Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 649,412 Open 18.92 Bid (Size) 21.00 (1) Ask (Size) 33.56 (2) Prev. Close 18.87 Today's Range 18.71 - 21.61 52wk Range 13.36 - 27.50 Shares Outstanding 27,433,359 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News BTIG Research Predicts Over 118% Rally for These 3 Stocks April 15, 2024 Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money. Via InvestorPlace Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week April 12, 2024 A powerfully bullish new analyst take on the company helped it rally on the market. Via The Motley Fool Performance YTD -3.23% -3.23% 1 Month -1.78% -1.78% 3 Month -11.05% -11.05% 6 Month +28.44% +28.44% 1 Year +0.77% +0.77% More News Read More Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session April 11, 2024 Via Benzinga Unveiling 4 Analyst Insights On AnaptysBio April 01, 2024 Via Benzinga Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday April 11, 2024 Via Benzinga Topics Stocks Exposures US Equities Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers March 12, 2024 Via Benzinga Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 11, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting February 29, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference January 31, 2024 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals November 27, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Named a BioSpace 2024 Best Places to Work Winner November 07, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update November 02, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Announces Participation in November Investor Conferences November 01, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress October 11, 2023 From AnaptysBio, Inc. Via GlobeNewswire Why Is Skin Disease Focused AnaptysBio Stock Trading Higher Today? October 09, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session October 09, 2023 Via Benzinga Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25 October 09, 2023 From AnaptysBio, Inc. Via GlobeNewswire Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) October 09, 2023 From AnaptysBio, Inc. Via GlobeNewswire Argenx's 28% Surge & Promising Product Propel Investor Confidence September 25, 2023 Via MarketBeat AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors September 18, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit September 12, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update August 07, 2023 From AnaptysBio, Inc. Via GlobeNewswire AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer July 31, 2023 From AnaptysBio, Inc. Via GlobeNewswire Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session July 31, 2023 Via Benzinga Stocks That Hit 52-Week Lows On Monday July 24, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.